Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*

• Glavni autori: Borislav Borissov (Autor), Michael Urbich (Autor), Boryana Georgieva (Autor), Svetoslav Tsenov (Autor), Guillermo Villa (Autor)
• Format: Knjiga
• Izdano: Taylor & Francis Group, 2017-01-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Background: An elevated level of low-density lipoprotein cholesterol (LDL-C) constitutes one of the most important modifiable risk factors for cardiovascular disease (CVD). Individuals with heterozygous familial hypercholesterolaemia (HeFH) are particularly vulnerable to CVD events. The addition of...